Advertisement
U.S. markets closed

Baroyeca Gold & Silver Inc. (BRYGF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.02280.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0228
Open0.0228
BidN/A x N/A
AskN/A x N/A
Day's Range0.0228 - 0.0228
52 Week Range0.0001 - 0.0483
Volume2,000
Avg. Volume6,252
Market Cap1.516M
Beta (5Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-0.1300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BRYGF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BAROYECA GOLD & SILVER INC
    Analyst Report: Baxter International Inc.Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
    Rating
    Fair Value
    Economic Moat
    6 hours agoMorningstar
View more
  • We're sorry we weren't able to find anything about this topic.